Glucose metabolism continuous deteriorating in male patients with human immunodeficiency virus accepted antiretroviral therapy for 156 weeks

Table 3 Multiple stepwise regression analysis of risk factors for glucose metabolism parameters within 156 wk (n = 61)

Independent variable	Dependent variable	B	SE	Beta	t	P value
FPG	Constant	5.416	0.233	-	23.206	< 0.0001
	VL	-0.040	0.016	-0.269	-2.470	0.015
	CD8+%	0.008	0.004	0.241	2.215	0.029
FINS	Constant	83.179	27.700	-	3.003	0.007
	ALT	0.348	0.081	0.670	4.302	< 0.0001
	VL	-6.654	2.375	-0.734	-2.801	0.011
	Follow-up weeks	-5.951	2.196	-0.711	-2.710	0.013
	CD8+ count (cells/μL)	-0.010	0.005	-0.325	-2.122	0.046
HOMA-IR	Constant	18.025	7.686	-	2.345	0.029
	ALT	0.090	0.023	0.642	3.855	0.001
	VL	-1.664	0.685	-0.405	-2.429	0.024
HOMA-β	Constant	695.830	224.509	-	3.099	0.016
	ALT	2.740	0.656	0.649	4.179	< 0.0001
	VL	-54.256	19.253	-0.440	-2.818	0.011
	CD8+ count (cells/μL)	-0.090	0.039	-0.345	-2.271	0.034

ALT: Alanine aminotransferase; FINS: Fasting insulin; FPG: Fasting plasma glucose; HOMA-IR: Homeostasis model assessment of insulin resistance; HOMA-β: Homeostasis model assessment of β cell function; VL: Viral load.